Biopharmaceutical News and Research

RSS

Advancing new antibiotics through the later stages of clinical testing

A report by University of Queensland researchers has warned a global crisis of antibiotic resistance is inevitable, despite promising developments in new antibiotics.

25 Jul 2023

ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

21 Jul 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board

PhoreMost Ltd. announced Professor Peter Parker and Dr Jason Imbriglio as members of its Scientific Advisory Board (SAB).

From PhoreMost 17 Jul 2023

Innovative mixed reality training platform to be developed for pharmaceutical companies and healthcare

UK immersive technology company FourPlus, along with collaborators Holosphere and the Cell and Gene Therapy Catapult, have been awarded funding from Innovate UK to create and test a mixed reality training platform that enables customised training delivery for pharmaceutical companies and healthcare.

17 Jul 2023

New clinical trial seeks a regenerative pharmaceutical solution for meniscal tears

With support from Amplicore, a University of Cincinnati spinoff biopharmaceutical company, researchers at UC have begun a Department of Defense-funded clinical trial that seeks a regenerative pharmaceutical solution for meniscal tears.

10 Jul 2023

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA.

From Sphere Fluidics 6 Jul 2023

Arima Genomics continues momentum toward clinic with formation of clinical advisory board

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to improve human health and drive discovery in the life sciences, today announced the formation of a clinical advisory board to help the company advance its 3D genomics technologies into the clinical oncology and biopharmaceutical markets.

From Arima Genomics, Inc. 5 Jul 2023

AANS, CNS urge CMS to finalize rules to improve prior authorization

Today, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) joined 61 bipartisan senators and 233 members of the House of Representatives in urging the U.S. Department of Health and Human Services and Centers for Medicare & Medicaid Services (CMS) to swiftly finalize rules to increase transparency, streamline and standardize prior authorization (PA).

4 Jul 2023

Multiple drug targets for the treatment of influenza identified using AI program

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence ('AI') Programme with CytoReason.

1 Jul 2023

Four pancreatic injury safety biomarkers identified and evaluated by PSTC

Critical Path Institute (C-Path) today announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA) issued a Biomarker Letter of Support (LOS) for four pancreatic injury safety biomarkers identified and evaluated by C-Path's Predictive Safety Testing Consortium's (PSTC) Pancreatic Injury Working Group (PIWG).

14 Jun 2023

Keynote speakers of ELRIG Drug Discovery 2023 announced

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focussing on diverse thinking and new perspectives.

10 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

8 Jun 2023

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

ELRIG Drug Discovery 2023 at ACC Liverpool (18–19 October) to focus on diverse thinking and new perspectives.

From ELRIG (UK) Ltd. 6 Jun 2023

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.

1 Jun 2023

Dutch scientists unveil the integral role of CD5L protein in IgM structure and function

Researchers in the Netherlands assessed the structure of human circulatory IgM and its relationship with the small CD5L protein.

31 May 2023

Survey reveals the limited knowledge about actinic keratosis among most people

Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, presented today the results of a survey revealing that 85% of respondents are unaware of the existence of actinic keratosis (AK).

25 May 2023

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.

22 May 2023

Valbenazine improves chorea associated with Huntington's disease

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

19 May 2023